NCT07279714 Fisetin in Mild Alzheimer's Disease
| NCT ID | NCT07279714 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Alzheimer s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2026-01-27 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 5 participants in total. It began in 2026-01-27 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Eligibility Criteria
Inclusion Criteria: * Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia * Moca score of 11 or higher * Stable psychotropics and cognitive enhancing medications Exclusion Criteria: * Known hypersensitivity or allergy to fisetin * Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial * Unstable medical disorders * Ongoing treatment for active infection with antibiotics/antifungals * Ongoing treatment for cancer * Active alcohol or substance use disorder * Recent active bleeding * Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin * Use within the last month of other senolytic supplements, antioxidant supplements, natural health products * Other neurologic or neurodegenerative conditions impacting cognition * Active Major Depressive Episode, active suicidal thoughts or psychosis * Any thing that would preclude the ability to undergo an MRI scan
Contact & Investigator
Krista Lanctôt, PhD
PRINCIPAL INVESTIGATOR
Sunnybrook Research Institute
Frequently Asked Questions
Who can join the NCT07279714 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07279714 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07279714 currently recruiting?
Yes, NCT07279714 is actively recruiting participants. Contact the research team at memoryresearch@sunnybrook.ca for enrollment information.
Where is the NCT07279714 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07279714 clinical trial?
NCT07279714 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is Krista Lanctôt, PhD at Sunnybrook Research Institute. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.